

BOARD OF ADVISORS

Michael Adler, US Army Medical Research Institute of Chemical Defense

Terry Bowlin, Microbiotix, Inc., USA

Klaus Fink, MERZ Pharma, Germany

David Hodge, US Department of Homeland Security

Andy Pickett, Toxin Sciences Ltd., UK

Shashi Sharma, US Food and Drug Administration

Kodumudi Venkateswaran, Omni Array Biotech, Inc., USA

Symposium Coordinators:

Shuowei Cai, University of Massachusetts Dartmouth

Raj Kumar, Institute of Advanced Sciences

Institute of Advanced Sciences

Botulinum Research Center 86-410 Faunce Corner Rd North Dartmouth MA, 02747 Tele: (

Fourth Announcement

15th Annual Botulinum Research Symposium, August 18-19, 2021

The 15th annual symposium organized by the Botulinum Research Center at the Institute of Advanced Sciences, Dartmouth, MA.

Theme: Redesigned Botulinum Neurotoxins

Tentative Program

9:00 - 9:30 AM

Wednesday, August 18, 2021 (Time, US Eastern Daylight Saving Time)

Session I -Inaugural Session	Chair: Michael Adler
------------------------------	----------------------

9:30 – 10:15 AM A chimeric toxin-based delivery platform for post-exposure treatment of botulism- Min Dong, Harvard Medical School 10:15 – 10:30 AM Q&A 10:30 – 10:45 AM Break Chair: TBA Local injection of an anti-cholinesterase restores muscle function post BoNT-A impairment – Sameer B. Shah, DelNova, Inc., USA 11:15 – 11:45 AM Treatment of botulism with 3,4-diaminopyridine – Michael Adler, US Army Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA 11:45 – 12:15 PM Inhibition of BoNT enzymatic activity with sodium phosphate – Suzy Kalb, CDC, Atlanta, USA 12:15 – 12:45 PM Lunch – cum – Poster breakout session		<u></u> ,,
10:30 – 10:45 AM Session II Chair: TBA Local injection of an anti-cholinesterase restores muscle function post BoNT-A impairment – Sameer B. Shah, DelNova, Inc., USA Treatment of botulism with 3,4-diaminopyridine – Michael Adler, US Army Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA Inhibition of BoNT enzymatic activity with sodium phosphate – Suzy Kalb, CDC, Atlanta, USA	9:30 – 10:15 AM	7 '
Session II Chair: TBA Local injection of an anti-cholinesterase restores muscle function post BoNT-A impairment – Sameer B. Shah, DelNova, Inc., USA Treatment of botulism with 3,4-diaminopyridine – Michael Adler, US Army Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA Inhibition of BoNT enzymatic activity with sodium phosphate – Suzy Kalb, CDC, Atlanta, USA	10:15 – 10:30 AM	Q&A
10:45 – 11:15 AM Local injection of an anti-cholinesterase restores muscle function post BoNT-A impairment – Sameer B. Shah, DelNova, Inc., USA 11:15 – 11:45 AM Treatment of botulism with 3,4-diaminopyridine – Michael Adler, US Army Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA 11:45 – 12:15 PM Inhibition of BoNT enzymatic activity with sodium phosphate – Suzy Kalb., CDC, Atlanta, USA	10:30 – 10:45 AM	Break
muscle function post BoNT-A impairment – Sameer B. Shah, DelNova, Inc., USA 11:15 – 11:45 AM Treatment of botulism with 3,4-diaminopyridine – Michael Adler, US Army Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA 11:45 – 12:15 PM Inhibition of BoNT enzymatic activity with sodium phosphate – Suzy Kalb., CDC, Atlanta, USA	Session II	Chair: TBA
US Army Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA 11:45 – 12:15 PM Inhibition of BoNT enzymatic activity with sodium phosphate – Suzy Kalb. CDC, Atlanta, USA	10:45 – 11:15 AM	muscle function post BoNT-A impairment – Sameer B.
Suzy Kalb., CDC, Atlanta, USA	11:15 – 11:45 AM	US Army Research Institute of Chemical Defense, Aberdeen Proving
12:15 – 12:45 PM Lunch – cum – Poster breakout session	11:45 – 12:15 PM	· · · · · · · · · · · · · · · · · · ·
	12:15 – 12:45 PM	Lunch – cum – Poster breakout session

Session III Chair: Brenda Wilson, Univ of Illinois

12:45 – 1:15 PM Redesigned botulinum neurotoxin endopeptidase and its potential use/misuse – Travis Blum, Harvard University

Welcome and Introductory Remarks - Bal Ram Singh, BRC, INADS

1:15 - 2:30 PM

Panel Discussion - Risk and Rewards of Redesigned Botulinum Neurotoxins - Andy Pickett,

Moderator

Klaus Fink, Merz, Germany Michael Adler, USARICD, USA Min Dong, Harvard Medical School Shuowei Cai, UMass Dartmouth

David Hodge, Former Program Officer, Homeland Security

Thursday, August 19, 2021

Session IV	Chair: TBA
9:00 – 9:10 AM	Introduction to the BR DasGupta Memorial Lecture – Bal Ram Singh and V. Sathyamoorthy
9:10 – 9:55 AM	Making of IncobotulinumtoxinA (Xeomin™), <u>Dr. Jurgen Frevert</u> , Merz Pharma, Germany
9:55 – 10:10 AM	Q&A
Session V	Chair: TBA
10:10 – 10:40 AM	Further Research Progress on Novel medical applications of botulinum neurotoxins – longevity and macular disease, <u>Gary Borodic</u> , Harvard Medical School, Boston, USA
10:40 – 11:10 AM	Gliosis mediated mechanism of Action of Isolated and Complete BoNT/A, Ghuncha Ambrin, UMass Dartmouth, MA, and Univ of North Carolina Charlotte, USA
11:10 – 11:25 AM	Break
Session VI	Chair: Andy Pickett, Toxin Bioscience
11:25 AM –12:25 PM	Lifetime Achievement Award - Speeches
Session VII	Chair: John Barr, CDC, Atlanta, USA
12:25 – 12:55 PM	Biosimilar Botulinum Neurotoxin Product- <u>Enan Guan</u> , Biologicsa & BoNT Consulting, Washington DC, USA
12:55 – 1:25 PM	Antibody-free Detection and Quantitation of Botulinum Neurotoxins by Nano LC with Targeted Multistage Mass Spectrometry- Markus Kalkum, Beckman Research Institute, USA
	1:25 – 1:55 PM Conformational Dynamics of Botulinum Toxin and its implication on evolution– Raj Kumar, Institute of Advanced Sciences, Dartmouth, USA
	1:55 – 2:25 PM

2:25 - 2:40 PM Closing

Zoom Conference registration - Join Zoom Meeting

https://us02web.zoom.us/j/8405225 6405?pwd=NFZBMzIrRXk3SVhY RFIUdVYyRi96UT09

Meeting ID: 840 5225 6405

Passcode: 096956